Down Syndrome

Abstract

Down syndrome, first described by Langdon Down in 1866, is caused by an extra copy of all or part of chromosome 21. It is the most commonly recognised genetic cause of intellectual disability and is characterised by a number of dysmorphic features and congenital malformations. The features of Down syndrome vary greatly from individual to individual, although some level of intellectual disability is always present as is hypotonia. The life expectancy of individuals with Down syndrome now approaches 60 years. The sequencing of the long arm of chromosome 21 was a milestone in research about Down syndrome but the complete understanding of the genetic information on the chromosome is still in progress. Several different mouse models with features reminiscent of aspects of Down syndrome have been produced. Although it is difficult to extrapolate from mice to humans, several studies using these mouse models suggest that it will be possible to develop therapies for aspects of Down syndrome, perhaps including intellectual disability.

Key Concepts:

  • The incidence of Down syndrome in the newborn population is in the vicinity of 1 per 700 live births in the United States and about 1 in 1000 in Europe. There is considerable variability in reported incidence in other parts of the world.

  • The condition of overriding critical importance in Down syndrome is intellectual disability.

  • The memory profile in Down syndrome is distinct from that seen in other phenotypic disorders associated with developmental disability such as Williams syndrome and Fragile x syndrome.

  • Pathological, metabolic and neurochemical changes of Alzheimer disease are present after the third decade in the brain of all individuals with Down syndrome.

  • With the changing patterns of institutionalisation and of the utilisation and methods of medical and surgical therapy, the mean life expectancy for persons with Down syndrome has improved dramatically in the last 50 years.

  • No pharmacological or dietary therapy as yet has been shown to have a beneficial effect on the intellectual disability associated with Down syndrome.

  • As one of the first triumphs of the Human Genome Project, the sequence of the long arm of chromosome 21 has been completed.

  • The successful amelioration of some of the learning and memory deficits and alterations in brain abnormalities in mouse models are encouraging since they support the hypothesis that successful post‚Äźnatal treatment of Down syndrome may be possible.

Keywords: intellectual disability; chromosome 21; trisomy; aneuploidy; Alzheimer disease; congenital heart disease; mouse models

References

Baird PA and Sadovnick AD (1987) Life expectancy in Down syndrome. Journal of Pediatrics 110: 849–854.

Bianchi P, Ciani E, Giudi S et al. (2010) Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. Journal of Neuroscience 30: 8769–8779.

Bittles AH, Bower C, Hussain R and Glasson EJ (2007) The four ages of Down syndrome. European Journal of Public Health 17: 221–225.

Costa AC, Scott‐McKean JJ and Stasko MR (2008) Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning task. Neuropsychopharmacology 33: 1624–1632.

Davisson MT, Schmidt C and Akeson EC (1990) Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. In: Patterson D and Epstein CJ (eds) Molecular Genetics of Chromosome 21 and Down Syndrome. Progress in Clinical and Biological Research, vol. 360, pp. 263–280. New York, NY: Wiley Liss.

Dolk H, Loane M and Garne E (2010) The prevalence of congenital anomalies in Europe. Advances in Experimental Medicine and Biology 686: 349–364.

Fernandez F, Morishita W, Zuniga E et al. (2007) Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nature Neuroscience 10: 411–413.

Groner Y (1995) Transgenic models for chromosome 21 gene dosage effects. In: Epstein CJ, Hassold T, Lott IT, Nadel L and Patterson D (eds) Etiology and Pathogenesis of Down Syndrome, pp. 193–212. New York, NY: Wiley‐Liss.

Hanson MJ (1987) Early intervention for children with Down syndrome. In: Pueschel SM, Tingey C, Rynders JE, Crocker AC and Crutcher DM (eds) New Perspectives on Down Syndrome, pp. 149–178. Baltimore, MD: PH Brooks.

Hattori M, Fujiyama A, Taylor TD et al. (2000) The DNA sequence of human chromosome 21. Nature 405: 311–319.

Korbel JO, Tirosh‐Wagner T, Urban AE et al. (2009) The genetic architecture of Down syndrome phenotypes revealed by high‐resolution analysis of human segmental trisomies. Proceedings of the National Academy of Sciences of the USA 106: 12031–12036.

Lamb NE, Feingold E, Savage A et al. (1997) Characterization of susceptible chiasma configurations that increase the risk for maternal nondisjunction of chromosome 21. Human Molecular Genetics 6: 1391–1399.

Leoncini E, Botto LD, Cocchi G et al. (2010) How valid are the rates of Down syndrome internationally? Findings from the International Clearinghouse for Birth Defects Surveillance and Research. American Journal of Medical Genetics Part A 152A: 1670–1680.

Lockrow J, Prakasam A, Huang P et al. (2009) Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Experimental Neurology 216: 278–289.

Lyle R, Bena F, Gagos S et al. (2009) Genotype–phenotype correlations in Down syndrome by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. European Journal of Human Genetics 17: 454–466.

Moon J, Chen M, Gandhy SU et al. (2010) Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behavioral Neuroscience 124: 346–361.

O'Doherty A, Ruf S, Mulligan C et al. (2005) An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309: 2033–2037.

Parker SE, Mai CT, Canfield MA et al. (2010) Updated National Birth prevalence estimates for selected birth defects in the United States, 2004–2006. Birth Defects Research A Clinical Molecular Teratology 88: 1008–1016.

Patterson D (2009) Molecular genetic analysis of Down syndrome. Human Genetics 126: 195–214.

Reeves RH, Irving NG, Moran T et al. (1995) A mouse model for Down syndrome exhibits learning and behavioral and deficit. Nature Genetics 11: 177–184.

Rumble B, Retallack R, Hilbich C et al. (1989) Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. New England Journal of Medicine 320: 1446–1452.

Salman M (2002) Systematic review of the effect of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome. European Journal of Paediatric Neurology 6: 213–219.

Sturgeon X and Gardiner KJ (2011) Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mammalian Genome 22: 261–271.

Yu T, Li Z, Jia Z et al. (2010) A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Human Molecular Genetics 19: 2780–2791.

Further Reading

Antonarakis SE and Epstein CJ (2006) The challenge of Down syndrome. Trends in Molecular Medicine 12: 473–479.

Dellarco VL, Voytek PE and Hollaender A (eds) (1985) Aneuploidy: Etiology and Mechanisms. New York, NY: Plenum.

Epstein CJ (1986) The Consequences of Chromosome Imbalance. Principals, Mechanisms, and Models. New York, NY: Cambridge University Press.

Epstein CJ (2001) Down syndrome (trisomy 21). In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds) The Metabolic Basis of Inherited Disease, 8th edn, pp. 1123–1256. New York, NY: McGraw‐Hill.

Epstein CJ (ed.) (1991) The Morphogenesis of Down Syndrome. New York, NY: Wiley‐Liss.

Epstein CJ (ed.) (1993) The Phenotype Mapping of Down Syndrome and Other Aneuploid Conditions. New York, NY: Wiley‐Liss.

Epstein CJ, Hassold T, Lott IT, Nadel L and Patterson D (eds) (1995) Etiology and Pathogenesis of Down Syndrome. New York, NY: Wiley‐Liss.

Gardiner K, Herault Y, Lott IT et al. (2010) Down syndrome: from understanding the neurobiology to therapy. Journal of Neuroscience 30: 14943–14945.

Lott IT and Dierssen M (2010) Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurology 9: 623–633.

Nadel L and Epstein CJ (eds) (1992) Downs Syndrome and Alzheimer Disease. New York, NY: Wiley‐Liss.

Patterson D and Costa AC (2005) Down syndrome and genetics – a case of linked histories. Nature Reviews Genetics 6: 137–147.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Patterson, David, and Lott, Ira T(Oct 2011) Down Syndrome. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0005711.pub2]